Precigen Inc

NASDAQ:PGEN  
4.66
-0.01 (-0.21%)
Products, Earnings Announcements

Precigen ActoBio Announces Additional Positive Interim Data From Phase 1B/2A Study Of AG019 ActoBiotics

Published: 10/01/2021 12:26 GMT
Precigen Inc (PGEN) - Precigen Actobio Announces Additional Positive Interim Data From Phase 1b/2a Study of Ag019 Actobiotics™, a Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes.
Precigen Inc - Ag019 Monotherapy and Ag019 Combination Therapy Resulted in Stabilization of Hba1c and Idaa1c Levels.
Precigen Inc - Mechanistic Analysis Showed Ag019 Treatment Resulted in Reduction of Conventional T-cells With an Inflammatory Phenotype.
Precigen - Metabolic Results Strengthen Previous Data on C-peptide, Antigen-specific Immune Modulation for Ag019 Monotherapy,ag019 Combination Therapy.
Precigen Inc - Monotherapy Results Suggest Potential for Ag019 As a Standalone Therapeutic Agent for T1d.
Revenue is expected to be $23.86 Million
Adjusted EPS is expected to be -$0.14

Next Quarter Revenue Guidance is expected to be $24.85 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.